Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed stage IIIB or IV recurrent or progressive NSCLC~* Patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the EGFR pathway~* Measurable disease, as defined by RECIST criteria~* Patients must have a suitable frozen or paraffin-embedded tissue sample available for EGFR mutational analysis. Prior EGFR mutational analyses are allowable~* Patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable~* ECOG Performance Status 0-2~* 18 years of age or older~* Negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential~* Bone marrow function, renal function, hepatic function as outlined in protocol~Exclusion Criteria:~* Women who are pregnant of breastfeeding~* Active concurrent malignancy~* Major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab~* Significant history of uncontrolled cardiac disease~* Uncontrolled seizure disorder, or active neurological disease~* Prior severe infusion reactions to a monoclonal antibody~* Prior chemotherapy regimen within 21 days prior to study entry~* Any EGFR tyrosine kinase inhibitor within 14 days of study entry~* Radiation therapy within 14 days prior to the first infusion of cetuximab~* Acute hepatitis or known HIV~* Active or uncontrolled infection~* Any concurrent chemotherapy or any other investigational agent(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: EXPERIMENTAL): 400mg/m2 IV x 1 and then 250mg/m2 IV weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).